Hansa Biopharma AB HNSA
OMXSTO · Sweden · Health Technology
SEK 34.06-0.06 (-0.18%)
Market open· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Hansa Biopharma AB (Nasdaq Stockholm: HNSA), a pioneer in treatments for rare IgG related immunologic conditions, today announced a partnership with Cradle, which builds the leading AI-driven protein design and engineering platform for biologics. Hansa will use Cradle's end-to-end platform across its discovery pipeline to design, optimize, and advance novel therapeutic candidates. Leveraging Cradle's AI driven protein engineering platform, the companies aim to accelerate the development of new t
Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix® (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).
Despite a slight revenue dip, Hansa Biopharma AB (FRA:24H) strengthens its European presence and prepares for a significant U.S. market opportunity.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.